
PACMA 31
CAS No. 1401089-31-3
PACMA 31( —— )
Catalog No. M28353 CAS No. 1401089-31-3
PACMA 31 is an irreversible and covalent inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. PACMA 31 significantly suppresses ovarian tumor growth and exhibits tumor targeting ability.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 53 | Get Quote |
![]() ![]() |
5MG | 87 | Get Quote |
![]() ![]() |
10MG | 147 | Get Quote |
![]() ![]() |
25MG | 327 | Get Quote |
![]() ![]() |
50MG | 533 | Get Quote |
![]() ![]() |
100MG | 767 | Get Quote |
![]() ![]() |
500MG | 1557 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePACMA 31
-
NoteResearch use only, not for human use.
-
Brief DescriptionPACMA 31 is an irreversible and covalent inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. PACMA 31 significantly suppresses ovarian tumor growth and exhibits tumor targeting ability.
-
DescriptionPACMA 31 is an irreversible and covalent inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. PACMA 31 significantly suppresses ovarian tumor growth and exhibits tumor targeting ability.(In Vitro):In OVCAR-8 cells, PACMA 31 (0-10 μM) potently inhibits colony formation in a dose-dependent manner.(In Vivo):In human ovarian cancer mouse xenografts, PACMA 31 (20-200 mg/kg) i.p. or per os administration of significantly inhibited tumor growth by 85% and 65% at day 62, respectively.
-
In Vitro——
-
In VivoAnimal Model:Athymic mice (bearing OVCAR-8 cells)Dosage:20-200 mg/kg Administration:I.p., per day for the first 3 wk with 5-d on and 2-d off treatment cycles, and dose was escalated to 40 mg/kg per day for the next 7 d; p.o., the initial dose of 20 mg/kg per day was gradually increased by 20 mg/kg per day with each dose for 3 d before it was orally dosed at 200 mg/kg per day for an additional 32 d, increasing the dose from 20 to 200 mg/kg Result:Compared with the control group, i.p. or per os administration of PACMA 31 significantly inhibited tumor growth by 85% and 65% at day 62, respectively.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorP-gp
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1401089-31-3
-
Formula Weight430.47
-
Molecular FormulaC21H22N2O6S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (232.30 mM)
-
SMILESO=C(C#C)N(C1=CC=C(OC)C=C1OC)C(C(=O)NCC(=O)OCC)C=2SC=CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yuan S, et al. Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. J Med Chem. 2021;64(19):14895-14911.
molnova catalog



related products
-
Isothymusin
Isothymusin( MIC= 200 microg/mL) exhibits inhibition activity against Mycobacterium tuberculosis. It ( IC50=7.7 microg/mL ) exhibits antioxidant activity against the radical scavenging ability of DPPH.
-
Isovitexin-2-O-rhamn...
Isovitexin-2''-O-rhamnoside has a role as an antifeedant and a plant metabolite.Antioxidant activities.Anti-hepatotoxic activities.
-
Fletikumab
Fletikumab (NNC0109-0012) is a monoclonal antibody that inhibits IL-20, primarily used in research on rheumatoid arthritis and psoriasis.